Skip to main content
Erschienen in: Osteoporosis International 2/2008

01.02.2008 | Original Article

Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women

verfasst von: H.-Y. Zhao, J.-M. Liu, G. Ning, Y.-J. Zhao, Y. Chen, L.-H. Sun, L.-Z. Zhang, M.-Y. Xu, J.-L. Chen

Erschienen in: Osteoporosis International | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Summary

Serum IGF-I level was negatively correlated with OPG and OPG/RANKL ratio, but positively correlated with RANKL. Serum OPG level in the highest quintile of IGF-I was significantly lower than that in the lowest. We conclude that the effect of IGF-I on bone remodeling may be mediated by the OPG/RANKL system.

Introduction

Insulin-like growth factor I (IGF-I) is an important factor in coupling bone remodeling, activating both formation and resorption. Compared with the many studies on the role of IGF-I in bone formation, the information regarding its effects on bone resorption is limited and conflicting. The balance of the two peptides produced by osteoblasts, osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand (RANKL), is critical for the bone resorption process. Our study was designed to analyze the relationships of serum concentrations of IGF-I with OPG, RANKL, OPG/RANKL ratio as well as BMDs in healthy Chinese women.

Methods

BMDs at lumbar spine and proximal femur in 504 pre- and postmenopausal women were measured by DXA. Serum levels of IGF-I, OPG and RANKL were also measured. Pearson’s correlation and partial correlation analysis, ANOVA, covariance analysis and stepwise multiple regression analysis were used as appropriate.

Results

Age was negatively correlated with serum levels of IGF-I (r = −0.702, p < 0.001). IGF-I was negatively correlated with OPG and OPG/RANKL ratio, but positively correlated with RANKL. The relationship between IGF-I and BMDs disappeared after adjustment for age. In postmenopausal women, IGF-I was lower in women with osteoporosis than in those with normal BMD (p = 0.056), but no differences were found among OPG, RANKL and OPG/RANKL ratio. Serum levels of OPG in the highest quintile of IGF-I were significantly lower than those in the lowest quintile of IGF-I, while no difference was found in RANKL. In the multiple regression analysis model, serum levels of IGF-I were the main determinants of the bone mass in Chinese women.

Conclusions

In conclusion, the relationship between decreasing IGF-I and BMDs in healthy Chinese women influenced by age, whereas the effect of IGF-I on bone remodeling (bone resorption) may be mediated by the OPG/RANKL system.
Literatur
2.
Zurück zum Zitat Zhao G, Monier-Faugere MC, Langub MC et al (2000) Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 141:2674–2682PubMedCrossRef Zhao G, Monier-Faugere MC, Langub MC et al (2000) Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 141:2674–2682PubMedCrossRef
3.
Zurück zum Zitat Jian GJ, Gronowicz G, Ledgard F et al (2000) Phenotypic characterization of transgenic mice with bone directed overexpression of IGF-I. J Bone Miner Res 15:S157 Jian GJ, Gronowicz G, Ledgard F et al (2000) Phenotypic characterization of transgenic mice with bone directed overexpression of IGF-I. J Bone Miner Res 15:S157
4.
Zurück zum Zitat Bikle D, Majumdar S, Laib A et al (2001) The skeletal structure of IGF-I deficient mice. J Bone Miner Res 16:1320–1330CrossRef Bikle D, Majumdar S, Laib A et al (2001) The skeletal structure of IGF-I deficient mice. J Bone Miner Res 16:1320–1330CrossRef
5.
Zurück zum Zitat Miyakoshi N, Kasukawa Y, Linkhart TA et al (2001) Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology 142:4349–4356PubMedCrossRef Miyakoshi N, Kasukawa Y, Linkhart TA et al (2001) Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology 142:4349–4356PubMedCrossRef
6.
Zurück zum Zitat Friedlander AL, Butterfield GE, Moynihan S et al (2001) One year of IGF-I treatment does not affect BMD, body composition, or psychological measures in postmenopausal women. J Clin Endocrinol Metab 86:1496–1503PubMedCrossRef Friedlander AL, Butterfield GE, Moynihan S et al (2001) One year of IGF-I treatment does not affect BMD, body composition, or psychological measures in postmenopausal women. J Clin Endocrinol Metab 86:1496–1503PubMedCrossRef
7.
Zurück zum Zitat Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinol 142:5050–5055CrossRef Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinol 142:5050–5055CrossRef
8.
Zurück zum Zitat Lacey DL, Timms E, Tan HL (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176PubMedCrossRef Lacey DL, Timms E, Tan HL (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176PubMedCrossRef
9.
Zurück zum Zitat Kostenuik PJ, Shalhoub V (2001) Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Res 7:613–635CrossRef Kostenuik PJ, Shalhoub V (2001) Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Res 7:613–635CrossRef
10.
Zurück zum Zitat Simonet WS, Lacey DL, Dunstan CR (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319PubMedCrossRef Simonet WS, Lacey DL, Dunstan CR (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319PubMedCrossRef
11.
Zurück zum Zitat Ma YL, Cain RL, Halladay DL et al (2001) Catabolic effects of continuous human PTH in vivo is associated with sustained stimulation of RANKL and inhibition of OPG and gene-associated bone formation. Endocrinology 142:4047–4054PubMedCrossRef Ma YL, Cain RL, Halladay DL et al (2001) Catabolic effects of continuous human PTH in vivo is associated with sustained stimulation of RANKL and inhibition of OPG and gene-associated bone formation. Endocrinology 142:4047–4054PubMedCrossRef
12.
Zurück zum Zitat Hofbauer LC, Gori F, Riggs BL et al (1999) Stimulation of OPGL and inhibition of OPG by glucocorticoids in human osteoblastic lineage cells. Endocrinology 140:4382–4389PubMedCrossRef Hofbauer LC, Gori F, Riggs BL et al (1999) Stimulation of OPGL and inhibition of OPG by glucocorticoids in human osteoblastic lineage cells. Endocrinology 140:4382–4389PubMedCrossRef
13.
Zurück zum Zitat Lee S, Lorezo J (1999) PTH stimulates trance and inhibits OPG mRNA. Endocrinology 140:3552–3561PubMedCrossRef Lee S, Lorezo J (1999) PTH stimulates trance and inhibits OPG mRNA. Endocrinology 140:3552–3561PubMedCrossRef
14.
Zurück zum Zitat Burguera B, Hofbauer LC, Thomas T et al (2001) Leptin reduces ovariectomy induced bone loss in rats. Endocrinology 142:3546–3553PubMedCrossRef Burguera B, Hofbauer LC, Thomas T et al (2001) Leptin reduces ovariectomy induced bone loss in rats. Endocrinology 142:3546–3553PubMedCrossRef
15.
Zurück zum Zitat Szulc P, Hofbauer LC, Delmas PD (2001) OPG serum levels in men: correlation with age, estrogen and testosterone status. J Clin Endocrinol Metab 86:3162–3165PubMedCrossRef Szulc P, Hofbauer LC, Delmas PD (2001) OPG serum levels in men: correlation with age, estrogen and testosterone status. J Clin Endocrinol Metab 86:3162–3165PubMedCrossRef
16.
Zurück zum Zitat Yakar S, Rosen CJ (2003) From mouse to man: redefining the role of insulin-like growth factor-I in the acquisition of bone mass. Exp Biol Med (Maywood) 228:245–252 Yakar S, Rosen CJ (2003) From mouse to man: redefining the role of insulin-like growth factor-I in the acquisition of bone mass. Exp Biol Med (Maywood) 228:245–252
17.
Zurück zum Zitat Ueland T (2005) GH/IGF-I and bone resorption in vivo and in vitro. Eur J Endocrinol 152:327–332PubMedCrossRef Ueland T (2005) GH/IGF-I and bone resorption in vivo and in vitro. Eur J Endocrinol 152:327–332PubMedCrossRef
18.
Zurück zum Zitat Rubin J, Ackert-Bicknell CL, Zhu L et al (2002) IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 87:4273–4279PubMedCrossRef Rubin J, Ackert-Bicknell CL, Zhu L et al (2002) IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 87:4273–4279PubMedCrossRef
19.
Zurück zum Zitat Gorny G, Shaw A, Oursler MJ (2004) IL-6 LIF and TNF-alpha regulation of GM-CSF inhibition of osteoclastogenesis in vitro. Exp Cell Res 294:149–158PubMedCrossRef Gorny G, Shaw A, Oursler MJ (2004) IL-6 LIF and TNF-alpha regulation of GM-CSF inhibition of osteoclastogenesis in vitro. Exp Cell Res 294:149–158PubMedCrossRef
20.
Zurück zum Zitat Liu JM, Zhao HY, Ning G et al (2005) Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20–75. Calcif Tissue Inter 76:1–6CrossRef Liu JM, Zhao HY, Ning G et al (2005) Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20–75. Calcif Tissue Inter 76:1–6CrossRef
21.
Zurück zum Zitat WHO Scientific Group Research on the menopause in the 1990’s (1996) A report of the WHO Scientific Group. World health Organization, Geneva, Switzerland 866:1–79 WHO Scientific Group Research on the menopause in the 1990’s (1996) A report of the WHO Scientific Group. World health Organization, Geneva, Switzerland 866:1–79
22.
Zurück zum Zitat WHO Assessment of fracture risk, its application t screening for postmenopausal osteoporosis (1994) Report of a WHO study Group. WHO Technical Report Series, No.843 WHO Assessment of fracture risk, its application t screening for postmenopausal osteoporosis (1994) Report of a WHO study Group. WHO Technical Report Series, No.843
23.
Zurück zum Zitat Langlois JA, Rosen CJ, Visser M et al (1998) Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham heart study. J Clin Endocrinol Metab 83:4257–4262PubMedCrossRef Langlois JA, Rosen CJ, Visser M et al (1998) Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham heart study. J Clin Endocrinol Metab 83:4257–4262PubMedCrossRef
24.
Zurück zum Zitat Martini G, Valenti R, Giovani S et al (2001) Influence of insulin-like growth factor-I and leptin on bone mass in healthy postmenopausal women. Bone 28:113–117PubMedCrossRef Martini G, Valenti R, Giovani S et al (2001) Influence of insulin-like growth factor-I and leptin on bone mass in healthy postmenopausal women. Bone 28:113–117PubMedCrossRef
25.
Zurück zum Zitat Seck T, Scheppach B, Scharla S et al (1998) Concentration of insulin-like growth factor (IGF)-I and II in iliac crest bone matrix from pre- and postmenopausal women: relationship to age, menopause, bone turnover, bone volume, and circulating IGFs. J Clin Endocrinol Metab 83:2331–2337PubMedCrossRef Seck T, Scheppach B, Scharla S et al (1998) Concentration of insulin-like growth factor (IGF)-I and II in iliac crest bone matrix from pre- and postmenopausal women: relationship to age, menopause, bone turnover, bone volume, and circulating IGFs. J Clin Endocrinol Metab 83:2331–2337PubMedCrossRef
26.
Zurück zum Zitat Seck T, Bretz A, Krempien R et al (1999) Age-related changes in insulin-like growth factor I and II in human femoral cortical bone: lack of correlation with bone mass. Bone 1999:387–393CrossRef Seck T, Bretz A, Krempien R et al (1999) Age-related changes in insulin-like growth factor I and II in human femoral cortical bone: lack of correlation with bone mass. Bone 1999:387–393CrossRef
27.
Zurück zum Zitat Poehlman ET, Toth MJ, Ades PA et al (1997) Menopause-associated changes in plasma lipids, insulin-like growth factor-I, and blood pressure: a longitudinal study. Eur J Clin Invest 27:322–326PubMedCrossRef Poehlman ET, Toth MJ, Ades PA et al (1997) Menopause-associated changes in plasma lipids, insulin-like growth factor-I, and blood pressure: a longitudinal study. Eur J Clin Invest 27:322–326PubMedCrossRef
28.
Zurück zum Zitat Romagnoli E, Minisola S, Carnevale V et al (1993) Effect of estrogen deficiency on IGF-I plasma levels: relationship with bone mineral density in perimenopausal women. Calcif Tissue Int 53:1–6PubMedCrossRef Romagnoli E, Minisola S, Carnevale V et al (1993) Effect of estrogen deficiency on IGF-I plasma levels: relationship with bone mineral density in perimenopausal women. Calcif Tissue Int 53:1–6PubMedCrossRef
29.
Zurück zum Zitat Ravn P, Overgaard K, Spencer EM et al (1995) Insulin-like growth factors I, and II in healthy women with and without established osteoporosis. Eur J Endocrinol 132:313–319PubMedCrossRef Ravn P, Overgaard K, Spencer EM et al (1995) Insulin-like growth factors I, and II in healthy women with and without established osteoporosis. Eur J Endocrinol 132:313–319PubMedCrossRef
30.
Zurück zum Zitat Sugimoto T, Nishiyama K, Kuribayashi F et al (1997) Serum levels of insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res 12:1272–1279PubMedCrossRef Sugimoto T, Nishiyama K, Kuribayashi F et al (1997) Serum levels of insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res 12:1272–1279PubMedCrossRef
31.
Zurück zum Zitat Liu JM, Zhao HY, Ning G et al (2007) IGF-I as an early marker for low bone mass or osteoporosis in pre- and postmenopausal women. J Bone Miner Metab (in press) Liu JM, Zhao HY, Ning G et al (2007) IGF-I as an early marker for low bone mass or osteoporosis in pre- and postmenopausal women. J Bone Miner Metab (in press)
32.
Zurück zum Zitat Bikle D, Majumdar S, Laib A et al (2001) The skeletal structure of IGF-I deficient mice. J Bone Miner Res 16:1320–1330CrossRef Bikle D, Majumdar S, Laib A et al (2001) The skeletal structure of IGF-I deficient mice. J Bone Miner Res 16:1320–1330CrossRef
33.
Zurück zum Zitat Fiorelli G, Formigli L, Zecchi Orlandini S et al (1996) Characterization and function of the receptor for IGF-I in human preosteoclastic cells. Bone 18:269–276PubMedCrossRef Fiorelli G, Formigli L, Zecchi Orlandini S et al (1996) Characterization and function of the receptor for IGF-I in human preosteoclastic cells. Bone 18:269–276PubMedCrossRef
34.
Zurück zum Zitat Hill PA, Reynolds JJ, Meikle MC (1995) Osteoblasts mediate insulin-like growth factor-I and -II stimulation of osteoclast formation and function. Endocrinology 136:124–131PubMedCrossRef Hill PA, Reynolds JJ, Meikle MC (1995) Osteoblasts mediate insulin-like growth factor-I and -II stimulation of osteoclast formation and function. Endocrinology 136:124–131PubMedCrossRef
35.
Zurück zum Zitat Wang YM, Nishida S, Elalieh HZ et al (2006) Role of IGF-I signaling in regulating osteoclastogenesis. J Bone Miner Res 21:1350–1358PubMedCrossRef Wang YM, Nishida S, Elalieh HZ et al (2006) Role of IGF-I signaling in regulating osteoclastogenesis. J Bone Miner Res 21:1350–1358PubMedCrossRef
36.
Zurück zum Zitat Lum L, Wong BR, Josien R (1999) Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dentritic cell survival. J Biol Chem 274:13613–13618PubMedCrossRef Lum L, Wong BR, Josien R (1999) Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dentritic cell survival. J Biol Chem 274:13613–13618PubMedCrossRef
37.
Zurück zum Zitat Theoleyre S, Kwan Tat S, Vusio P et al (2006) Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: Role in the interactions with receptor activator of nuclear factor κB ligand (RANKL) and RANK. Biochem Biophy Res Commun 347:460–467CrossRef Theoleyre S, Kwan Tat S, Vusio P et al (2006) Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: Role in the interactions with receptor activator of nuclear factor κB ligand (RANKL) and RANK. Biochem Biophy Res Commun 347:460–467CrossRef
Metadaten
Titel
Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women
verfasst von
H.-Y. Zhao
J.-M. Liu
G. Ning
Y.-J. Zhao
Y. Chen
L.-H. Sun
L.-Z. Zhang
M.-Y. Xu
J.-L. Chen
Publikationsdatum
01.02.2008
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe 2/2008
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-007-0440-y

Weitere Artikel der Ausgabe 2/2008

Osteoporosis International 2/2008 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärztinnen und Psychotherapeuten.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.